Furthermore, our analysis of PELP1 expression in various cancers that arise from a pre-existing chronic inflammatory background in a progression model of normal–inflammation–cancer disease spectrum showed a progressive increase in PELP1 expression in gastric, colon, breast, cervical, and prostate cancers. Here, PELP1 is linked to prostate cancer.